Mammary Cell News Volume 6.24 | Jun 26 2014

HSF1 Regulation of β-Catenin in Mammary Cancer Cells through Control of HuR/elavL1 Expression
Researchers investigated a role for heat shock factor 1 (HSF1) in regulating the expression of the stem cell renewal factor β-catenin in immortalized human mammary epithelial and carcinoma cells. [Oncogene] Abstract

Metabolic Profiling Reveals PAFAH1B3 as a Critical Driver of Breast Cancer Pathogenicity
Researchers used metabolic mapping platforms to identify biochemical drivers of cellular transformation and malignant progression driven through RAS and the Hippo pathway in breast cancer and identified platelet-activating factor acetylhydrolase 1B3 (PAFAH1B3) as a key metabolic driver of breast cancer pathogenicity that is upregulated in primary human breast tumors and correlated with poor prognosis. [Chem Biol]
Abstract | Graphical Abstract

In Vivo and In Vitro Properties of STX2484: A Novel Non-Steroidal Anti-Cancer Compound Active in Taxane-Resistant Breast Cancer
Scientists aimed to identify STX2484’s mechanism of action, in vivo efficacy and activity in taxane-resistant breast cancer models. Effects of STX2484 and paclitaxel on proliferation, cell cycle and apoptosis were assessed in vitro in drug-resistant and non-resistant cells. [Br J Cancer] Abstract

Global Analysis of ZNF217 Chromatin Occupancy in the Breast Cancer Cell Genome Reveals an Association with ERalpha
Scientists present a large-scale functional genomic analysis of ZNF217, which provides insights into the regulatory role of ZNF217 in MCF7 breast cancer cells. [BMC Genomics] Abstract | Full Article

GALNT14 Mediates Tumor Invasion and Migration in Breast Cancer Cell MCF-7
Researchers modulated the expression of N-acetylgalactosaminyltransferase14 (GALNT14) by RNAi and overexpression in MCF-7 cells. Overexpression of GALNT14 significantly enhanced cell migration and invasion and promoted the proliferation of breast cancer cells. [Mol Carcinog] Abstract

Verrucarin A Induces Apoptosis through ROS-Mediated EGFR/MAPK/Akt Signaling Pathways in MDA-MB-231 Breast Cancer Cells
Scientists elucidated the mechanisms underlying Verrucarin A (VA)-induced cytotoxicity in human breast cancer cell line MDA-MB-231. VA inhibited the growth of MDA-MB-231 cells by induction of ROS-dependent mitochondrial apoptosis. [J Cell Biochem] Abstract

Cytotoxic Effects of Mangifera indica L. Kernel Extract on Human Breast Cancer (MCF-7 and MDA-MB-231 Cell Lines) and Bioactive Constituents in the Crude Extract
The potential anticancer effects of ethanolic kernel extract on breast cancer cells using MTT, anti-proliferation, neutral red uptake and lactate dehydrogenase release assays were evaluated. [BMC Complement Altern Med] Abstract | Full Article

Differential Requirement of GRP94 and GRP78 in Mammary Gland Development
Conditional knockout mouse models have revealed tissue specific requirements for GRP94 and GRP78, including selection for allele retention in specific cell types. Scientists report the consequences of mammary-targeted knockout of these glucose regulated proteins. [Sci Rep] Full Article

CLINICAL RESEARCH

Identification of Single-Nucleotide Polymorphisms Associated with Response of Breast Cancer Patients to Neoadjuvant Chemotherapy in the EORTC-10994 Randomized Phase III Trial
Scientists genotyped a subset of patients included in a neoadjuvant breast cancer trial to explore the relationship between genotypes and clinical outcome according to treatment received and p53 status. [Pharmacogenomics J] Abstract

Randomized, Phase II, Placebo-Controlled, Trial of Fulvestrant Plus Vandetanib in Postmenopausal Women with Bone Only or Bone Predominant, Hormone-Receptor-Positive Metastatic Breast Cancer (MBC): The OCOG ZAMBONEY Study
Scientists assessed whether vandetanib, an inhibitor of vascular endothelial growth factor, epidermal growth factor receptor and RET signaling, improved urine N-telopeptide response when added to fulvestrant in breast cancer patients with bone metastases. [Breast Cancer Res Treat] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Western Oncolytics Receives $275,000 Seed Funding for Development of Cancer Immunotherapy
Western Oncolytics Ltd. has closed $275,000 in seed funding. The proceeds are planned to set a path toward clinical trials and execute initial manufacturing for its novel virus-based cancer therapy, which delivers genes to guide the immune system to kill cancer cells. [PR Newswire Association LLC] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

PhD Candidate – ECM Proteins in Breast Cancer Progression and Metastasis (Norwegian University of Science and Technology)

Postdoctoral Associates – Morphogenesis of the Mammary Gland (Princeton University)

Postdoctoral Candidates – Cell Biology (Albert Einstein College of Medicine)

PhD Research Fellow – Molecular Cancer Research (Norwegian University of Science and Technology)

Postdoctoral Fellow – Cancer Biology (The University of Queensland)

Postdoctoral Fellow – Tumor Microenvironment of Bone Metastasis of Breast and Prostate Cancer (University of Edinburgh)

Postdoctoral Scholar – Cancer and RNA Research (Northwestern University)

Postdoctoral Research Associates – Pattern Formation during Branching Morphogenesis of the Mammary Gland (Princeton University)

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.